{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T03:37:00Z","timestamp":1794627420595,"version":"4.9.1"},"reference-count":121,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004366","name":"Tabriz University of Medical Sciences","doi-asserted-by":"publisher","award":["65016"],"award-info":[{"award-number":["65016"]}],"id":[{"id":"10.13039\/501100004366","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.biopha.2025.118249","type":"journal-article","created":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T19:31:01Z","timestamp":1750102261000},"page":"118249","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Therapeutic implications of obeticholic acid, a farnesoid X receptor agonist, in the treatment of liver fibrosis"],"prefix":"10.1016","volume":"189","author":[{"given":"Arezou","family":"Azizsoltani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahare","family":"Niknam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Taghizadeh-Teymorloei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erfan","family":"Ghoodjani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Dianat-Moghadam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7481-0896","authenticated-orcid":false,"given":"Effat","family":"Alizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.biopha.2025.118249_bib1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","article-title":"Molecular and cellular mechanisms of liver fibrosis and its regression","volume":"18","author":"Kisseleva","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"10","key":"10.1016\/j.biopha.2025.118249_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/cells10102759","article-title":"Cellular and molecular mechanisms underlying liver fibrosis regression","volume":"10","author":"Caligiuri","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2025.118249_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116848","article-title":"Progress of mesenchymal stem cells (MSCs) & MSC-exosomes combined with drugs intervention in liver fibrosis","volume":"176","author":"Xu","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.biopha.2025.118249_bib4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s43162-024-00283-y","article-title":"Emerging advanced approaches for diagnosis and inhibition of liver fibrogenesis","volume":"36","author":"Addissouky","year":"2024","journal-title":"Egypt. J. Intern. Med."},{"key":"10.1016\/j.biopha.2025.118249_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110294","article-title":"Human Wharton's jelly mesenchymal stem cells derived-exosomes enriched by miR-124 promote an anti-fibrotic response in an experimental model of liver fibrosis","volume":"119","author":"Niknam","year":"2023","journal-title":"Int. Immunopharmacol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118249_bib6","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1478-3231.2005.01163.x","article-title":"Portal hypertension: from pathophysiology to clinical practice","volume":"25","author":"Laleman","year":"2005","journal-title":"Liver Int."},{"issue":"40","key":"10.1016\/j.biopha.2025.118249_bib7","doi-asserted-by":"crossref","first-page":"6111","DOI":"10.3748\/wjg.v26.i40.6111","article-title":"Cirrhotic portal hypertension: from pathophysiology to novel therapeutics","volume":"26","author":"Gunarathne","year":"2020","journal-title":"World J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118249_bib8","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/hep.32285","article-title":"Hepatic fibrosis 2022: unmet needs and a blueprint for the future","volume":"75","author":"Friedman","year":"2022","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.biopha.2025.118249_bib9","article-title":"Liver fibrosis: pathophysiology and clinical implications","volume":"13","author":"Berumen","year":"2021","journal-title":"WIREs Mech. Dis."},{"issue":"24","key":"10.1016\/j.biopha.2025.118249_bib10","doi-asserted-by":"crossref","first-page":"9448","DOI":"10.1073\/pnas.1201840109","article-title":"Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis","volume":"109","author":"Kisseleva","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.biopha.2025.118249_bib11","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1136\/gutjnl-2021-324305","article-title":"Novel therapeutic targets for cholestatic and fatty liver disease","volume":"71","author":"Trauner","year":"2022","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.biopha.2025.118249_bib12","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/cld.641","article-title":"Antifibrotic therapies in liver disease: ready for primetime?","volume":"9","author":"Rudnick","year":"2017","journal-title":"Clin. Liver Dis."},{"issue":"8","key":"10.1016\/j.biopha.2025.118249_bib13","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.metabol.2016.04.004","article-title":"Pharmacological management of nonalcoholic fatty liver disease","volume":"65","author":"Barb","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.biopha.2025.118249_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.874408","article-title":"New drugs for hepatic fibrosis","volume":"13","author":"Shan","year":"2022","journal-title":"Front Pharmacol."},{"key":"10.1016\/j.biopha.2025.118249_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2021.808603","article-title":"Farnesoid X receptor activation in brain alters brown adipose tissue function via the sympathetic system","volume":"14","author":"Deckmyn","year":"2022","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.biopha.2025.118249_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2022.111618","article-title":"Discovery of farnesoid X receptor and its role in bile acid metabolism","volume":"548","author":"Chiang","year":"2022","journal-title":"Mol. Cell Endocrinol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118249_bib17","first-page":"S46","article-title":"Treatment of nonalcoholic steatohepatitis by obeticholic acid: current status","volume":"12","author":"Roy","year":"2022","journal-title":"Eur. J. Hepatogastroenterol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118249_bib18","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S1665-2681(19)31286-4","article-title":"Obeticholic acid: expanding the therapeutic landscape of NASH","volume":"14","author":"Arrese","year":"2015","journal-title":"Ann. Hepatol."},{"key":"10.1016\/j.biopha.2025.118249_bib19","article-title":"NAFLD: Obeticholic acid for the treatment of fatty liver disease-NASH no more?","volume":"12","author":"Ray","year":"2014","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2025.118249_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2021.101675","article-title":"Efficacy and safety of obeticholic acid in liver disease-a systematic review and meta-analysis","volume":"45","author":"Kulkarni","year":"2021","journal-title":"Clin. Res. Hepatol. Gastroenterol."},{"key":"10.1016\/j.biopha.2025.118249_bib21","article-title":"REGENERATE: design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis","volume":"84","author":"Ratziu","year":"2019","journal-title":"Conte Clin. Trials"},{"issue":"1","key":"10.1016\/j.biopha.2025.118249_bib22","doi-asserted-by":"crossref","first-page":"8157","DOI":"10.1038\/s41598-018-26383-8","article-title":"Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis","volume":"8","author":"Goto","year":"2018","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.biopha.2025.118249_bib23","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1053\/j.gastro.2008.03.003","article-title":"Mechanisms of hepatic fibrogenesis","volume":"134","author":"Friedman","year":"2008","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.biopha.2025.118249_bib24","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1038\/s41467-020-16092-0","article-title":"Hepatocyte mitochondria-derived danger signals directly activate hepatic stellate cells and drive progression of liver fibrosis","volume":"11","author":"An","year":"2020","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.biopha.2025.118249_bib25","first-page":"634","article-title":"TIMP-1 Promotes Expression of MCP-1 and Macrophage Migration by Inducing Fli-1 in Experimental Liver Fibrosis","volume":"12","author":"Huang","year":"2024","journal-title":"J. Clin. Transl. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118249_bib26","doi-asserted-by":"crossref","first-page":"7299","DOI":"10.1038\/s41598-019-43759-6","article-title":"Matrix stiffness modulates the activity of MMP-9 and TIMP-1 in hepatic stellate cells to perpetuate fibrosis","volume":"9","author":"Lachowski","year":"2019","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.biopha.2025.118249_bib27","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/hep.28932","article-title":"Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis","volume":"65","author":"Samur","year":"2017","journal-title":"Hepatology"},{"issue":"10215","key":"10.1016\/j.biopha.2025.118249_bib28","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.biopha.2025.118249_bib29","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/0092-8674(95)90530-8","article-title":"Identification of a nuclear receptor that is activated by farnesol metabolites","volume":"81","author":"Forman","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2025.118249_bib30","doi-asserted-by":"crossref","first-page":"33453","DOI":"10.1038\/srep33453","article-title":"FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis","volume":"6","author":"Verbeke","year":"2016","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.biopha.2025.118249_bib31","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1002\/hep.26939","article-title":"Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats","volume":"59","author":"Verbeke","year":"2014","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.biopha.2025.118249_bib32","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1053\/j.gastro.2004.08.001","article-title":"The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis","volume":"127","author":"Fiorucci","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2025.118249_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2019.105911","article-title":"Obeticholic acid prevents carbon tetrachloride-induced liver fibrosis through interaction between farnesoid X receptor and Smad3","volume":"77","author":"Fan","year":"2019","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118249_bib34","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1124\/jpet.105.085597","article-title":"Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis","volume":"315","author":"Fiorucci","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2025.118249_bib35","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1124\/jpet.105.084905","article-title":"A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis","volume":"314","author":"Fiorucci","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2025.118249_bib36","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ajpath.2014.10.009","article-title":"The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats","volume":"185","author":"Verbeke","year":"2015","journal-title":"Am. J. Pathol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118249_bib37","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/j.jhep.2015.12.010","article-title":"Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats","volume":"64","author":"\u00dabeda","year":"2016","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118249_bib38","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1124\/jpet.104.079665","article-title":"Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis","volume":"313","author":"Fiorucci","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.biopha.2025.118249_bib39","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1038\/s41598-020-58562-x","article-title":"Obeticholic acid and INT-767 modulate collagen deposition in a NASH in vitro model","volume":"10","author":"Anfuso","year":"2020","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.biopha.2025.118249_bib40","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1158\/0008-5472.CAN-06-1078","article-title":"Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor","volume":"67","author":"Yang","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2025.118249_bib41","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.5604\/01.3001.0010.5498","article-title":"Bile acids in nonalcoholic fatty liver disease: new concepts and therapeutic advances","volume":"16","author":"Cruz-Ram\u00f3n","year":"2017","journal-title":"Ann. Hepatol."},{"issue":"8","key":"10.1016\/j.biopha.2025.118249_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2021.166145","article-title":"Emerging functions of the nuclear receptor LRH-1 in liver physiology and pathology","volume":"1867","author":"Sun","year":"2021","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"issue":"3","key":"10.1016\/j.biopha.2025.118249_bib43","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S1097-2765(00)00051-4","article-title":"A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis","volume":"6","author":"Goodwin","year":"2000","journal-title":"Mol. Cell"},{"issue":"3","key":"10.1016\/j.biopha.2025.118249_bib44","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.livres.2021.02.002","article-title":"Farnesoid X receptor and fibroblast growth factor 15\/19 as pharmacological targets","volume":"5","author":"Maliha","year":"2021","journal-title":"Liver Res."},{"issue":"11","key":"10.1016\/j.biopha.2025.118249_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23116046","article-title":"Molecular Basis of Bile Acid-FXR-FGF15\/19 Signaling Axis","volume":"23","author":"Katafuchi","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2025.118249_bib46","first-page":"303","article-title":"Bioinformatics\u2011based identification of key pathways and candidate genes for estrogen\u2011induced intrahepatic cholestasis using DNA microarray analysis","volume":"20","author":"Xiang","year":"2019","journal-title":"Mol. Med. Rep."},{"issue":"4","key":"10.1016\/j.biopha.2025.118249_bib47","first-page":"1508","article-title":"Farnesoid X receptor: from structure to function and its pharmacology in liver fibrosis","volume":"15","author":"Ding","year":"2024","journal-title":"Aging Dis."},{"key":"10.1016\/j.biopha.2025.118249_bib48","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.tiv.2016.11.014","article-title":"Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system","volume":"39","author":"Dash","year":"2017","journal-title":"Toxicol. In Vitro"},{"issue":"5","key":"10.1016\/j.biopha.2025.118249_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/biology11050792","article-title":"PPAR alpha as a metabolic modulator of the liver: role in the pathogenesis of nonalcoholic steatohepatitis (NASH)","volume":"11","author":"Todisco","year":"2022","journal-title":"Biology"},{"key":"10.1016\/j.biopha.2025.118249_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113577","article-title":"A new perspective on NAFLD: focusing on the crosstalk between peroxisome proliferator-activated receptor alpha (PPAR\u03b1) and farnesoid X receptor (FXR)","volume":"154","author":"Zhou","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.biopha.2025.118249_bib51","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1124\/jpet.108.144600","article-title":"Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet","volume":"328","author":"Kong","year":"2009","journal-title":"J. Pharm. Exp. Ther."},{"key":"10.1016\/j.biopha.2025.118249_bib52","first-page":"93","article-title":"Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system","volume":"39","author":"Dash","year":"2017","journal-title":"Toxicol"},{"issue":"1","key":"10.1016\/j.biopha.2025.118249_bib53","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2019.10.006","article-title":"Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis","volume":"72","author":"Siddiqui","year":"2020","journal-title":"J. Hepatol."},{"issue":"11","key":"10.1016\/j.biopha.2025.118249_bib54","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1111\/liv.14209","article-title":"CONTROL: a randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients","volume":"39","author":"Pockros","year":"2019","journal-title":"Liver Int."},{"issue":"4","key":"10.1016\/j.biopha.2025.118249_bib55","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1124\/mol.106.023820","article-title":"The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo","volume":"70","author":"Rizzo","year":"2006","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.biopha.2025.118249_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1214685","article-title":"The regulatory role of bile acid microbiota in the progression of liver cirrhosis","volume":"14","author":"Zhu","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2025.118249_bib57","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.5604\/01.3001.0010.5672","article-title":"The role of the gut microbiota in bile acid metabolism","volume":"16","author":"Ram\u00edrez-P\u00e9rez","year":"2017","journal-title":"Ann. Hepatol."},{"issue":"22","key":"10.1016\/j.biopha.2025.118249_bib58","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242216502","article-title":"Gut microbiota and bacterial translocation in the pathogenesis of liver fibrosis","volume":"24","author":"Maslennikov","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118249_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2020.571847","article-title":"Gut microbiome contributes to liver fibrosis impact on T cell receptor immune repertoire","volume":"11","author":"Liang","year":"2020","journal-title":"Front. Microbiol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118249_bib60","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jhep.2024.09.032","article-title":"Bile acid metabolism and signalling in liver disease","volume":"82","author":"Fuchs","year":"2025","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118249_bib61","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41522-022-00352-6","article-title":"Host-microbiome interactions: gut-Liver axis and its connection with other organs","volume":"8","author":"Anand","year":"2022","journal-title":"npj Biofilms Microb."},{"key":"10.1016\/j.biopha.2025.118249_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2024.1411843","article-title":"Biliary atresia: the role of gut microbiome, and microbial metabolites","volume":"14","author":"Feng","year":"2024","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.biopha.2025.118249_bib63","doi-asserted-by":"crossref","first-page":"3","DOI":"10.21037\/tgh.2020.02.18","article-title":"Gut microbiome changes in Nonalcoholic fatty liver disease & alcoholic liver disease","volume":"6","author":"Kwong","year":"2021","journal-title":"Transl. Gastroenterol. Hepatol."},{"key":"10.1016\/j.biopha.2025.118249_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.814496","article-title":"Liver Fibrosis\u2014from mechanisms of injury to modulation of disease","volume":"8","author":"Liedtke","year":"2022","journal-title":"Front. Med."},{"issue":"2","key":"10.1016\/j.biopha.2025.118249_bib65","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/med.21991","article-title":"FXR agonists for MASH therapy: lessons and perspectives from obeticholic acid","volume":"44","author":"Wang","year":"2024","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.biopha.2025.118249_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2022.111650","article-title":"Immunomodulatory functions of FXR","volume":"551","author":"Fiorucci","year":"2022","journal-title":"Mol. Cell Endocrinol."},{"issue":"1-2","key":"10.1016\/j.biopha.2025.118249_bib67","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.mce.2014.01.014","article-title":"Nonalcoholic steatohepatitis as a novel player in metabolic syndrome-induced erectile dysfunction: an experimental study in the rabbit","volume":"384","author":"Vignozzi","year":"2014","journal-title":"Mol. Cell Endocrinol."},{"issue":"10","key":"10.1016\/j.biopha.2025.118249_bib68","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/hep4.1127","article-title":"Targeting bile acids and lipotoxicity for NASH treatment","volume":"1","author":"Chiang","year":"2017","journal-title":"Hepatol. Commun."},{"issue":"2","key":"10.1016\/j.biopha.2025.118249_bib69","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.gendis.2021.12.006","article-title":"Mechanisms of NLRP3 inflammasome-mediated hepatic stellate cell activation: therapeutic potential for liver fibrosis","volume":"10","author":"Charan","year":"2023","journal-title":"Genes Dis."},{"issue":"6","key":"10.1016\/j.biopha.2025.118249_bib70","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20061295","article-title":"Interleukin-1 receptor antagonist modulates liver inflammation and fibrosis in mice in a model-dependent manner","volume":"20","author":"Meier","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118249_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154797","article-title":"A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage","volume":"120","author":"Huang","year":"2021","journal-title":"Metabolism"},{"issue":"22","key":"10.1016\/j.biopha.2025.118249_bib72","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1042\/CS20190068","article-title":"Processes exacerbating apoptosis in non-alcoholic steatohepatitis","volume":"133","author":"Afonso","year":"2019","journal-title":"Clin. Sci."},{"key":"10.1016\/j.biopha.2025.118249_bib73","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.taap.2016.11.006","article-title":"Obeticholic acid protects against carbon tetrachloride-induced acute liver injury and inflammation","volume":"314","author":"Zhang","year":"2017","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118249_bib74","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151736","article-title":"Extracellular matrix molecular remodeling in human liver fibrosis evolution","volume":"11","author":"Baiocchini","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2025.118249_bib75","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.matbio.2017.12.012","article-title":"Matrix metalloproteinases and liver fibrosis (translational aspects)","volume":"68-69","author":"Roeb","year":"2018","journal-title":"Matrix Biol."},{"issue":"12","key":"10.1016\/j.biopha.2025.118249_bib76","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1038\/s41419-021-04377-1","article-title":"Initiation of hepatic stellate cell activation extends into chronic liver disease","volume":"12","author":"De Smet","year":"2021","journal-title":"Cell Death Dis."},{"issue":"6","key":"10.1016\/j.biopha.2025.118249_bib77","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1139\/o96-088","article-title":"Molecular regulation of cellular invasion\u2014 role of gelatinase A and TIMP-2","volume":"74","author":"Yu","year":"1996","journal-title":"Biochem. Cell Biol."},{"key":"10.1016\/j.biopha.2025.118249_bib78","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.730176","article-title":"Liver fibrosis: therapeutic targets and advances in drug therapy","volume":"9","author":"Tan","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"3","key":"10.1016\/j.biopha.2025.118249_bib79","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.apsb.2018.11.004","article-title":"Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis","volume":"9","author":"Zhou","year":"2019","journal-title":"Acta Pharm. Sin. B"},{"issue":"12","key":"10.1016\/j.biopha.2025.118249_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2021.166235","article-title":"Nuclear receptors in liver fibrosis","volume":"1867","author":"K\u00f6nigshofer","year":"2021","journal-title":"Biochim Biophys. Acta Mol. Basis Dis."},{"issue":"3","key":"10.1016\/j.biopha.2025.118249_bib81","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.gastha.2023.09.013","article-title":"Farnesoid X receptor agonists: a promising therapeutic strategy for gastrointestinal diseases","volume":"3","author":"Almeqdadi","year":"2024","journal-title":"Gastro Hep Adv."},{"key":"10.1016\/j.biopha.2025.118249_bib82","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.2147\/DDDT.S310163","article-title":"The agonists of peroxisome proliferator-activated receptor-\u03b3 for liver fibrosis","volume":"15","author":"Li","year":"2021","journal-title":"Drug Des. Dev. Ther."},{"issue":"2","key":"10.1016\/j.biopha.2025.118249_bib83","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1210\/me.2002-0120","article-title":"Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor","volume":"17","author":"Pineda Torra","year":"2003","journal-title":"Mol. Endocrinol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118249_bib84","doi-asserted-by":"crossref","first-page":"F1587","DOI":"10.1152\/ajprenal.00404.2009","article-title":"The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria","volume":"297","author":"Wang","year":"2009","journal-title":"Am. J. Physiol. Ren. Physiol."},{"issue":"2","key":"10.1016\/j.biopha.2025.118249_bib85","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00018-012-1046-x","article-title":"Peroxisome proliferator-activated receptor-\u03b3 as a therapeutic target for hepatic fibrosis: from bench to bedside","volume":"70","author":"Zhang","year":"2013","journal-title":"Cell Mol. Life Sci."},{"issue":"2","key":"10.1016\/j.biopha.2025.118249_bib86","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/SHK.0000000000001001","article-title":"On the role of illness duration and nutrient restriction in cholestatic alterations that occur during critical illness","volume":"50","author":"Jenniskens","year":"2018","journal-title":"Shock"},{"issue":"5","key":"10.1016\/j.biopha.2025.118249_bib87","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/hep.22519","article-title":"Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response","volume":"48","author":"Wang","year":"2008","journal-title":"Hepatology"},{"issue":"22","key":"10.1016\/j.biopha.2025.118249_bib88","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232213967","article-title":"The farnesoid X receptor as a master regulator of hepatotoxicity","volume":"23","author":"Rausch","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.biopha.2025.118249_bib89","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.molmet.2017.09.001","article-title":"Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice","volume":"6","author":"Jouihan","year":"2017","journal-title":"Mol. Metab."},{"issue":"1","key":"10.1016\/j.biopha.2025.118249_bib90","doi-asserted-by":"crossref","first-page":"9046","DOI":"10.1038\/s41598-019-45178-z","article-title":"Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob\/ob mouse model of biopsy-confirmed NASH","volume":"9","author":"Roth","year":"2019","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.biopha.2025.118249_bib91","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3892\/etm.2021.10262","article-title":"Co-administration of obeticholic acid and simvastatin protects against high-fat diet-induced non-alcoholic steatohepatitis in mice","volume":"22","author":"Li","year":"2021","journal-title":"Exp. Ther. Med"},{"issue":"1","key":"10.1016\/j.biopha.2025.118249_bib92","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41467-019-14138-6","article-title":"SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis","volume":"11","author":"Zhou","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2025.118249_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115777","article-title":"Obeticholic acid-loaded exosomes attenuate liver fibrosis through dual targeting of the FXR signaling pathway and ECM remodeling","volume":"168","author":"Azizsoltani","year":"2023","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.biopha.2025.118249_bib94","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s12664-021-01220-5","article-title":"Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on ongoing hepatic fibrosis","volume":"41","author":"Namisaki","year":"2022","journal-title":"Indian J. Gastroenterol."},{"issue":"10","key":"10.1016\/j.biopha.2025.118249_bib95","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1111\/hepr.13385","article-title":"Combined effect of a farnesoid X receptor agonist and dipeptidyl peptidase-4 inhibitor on hepatic fibrosis","volume":"49","author":"Shimozato","year":"2019","journal-title":"Hepatol. Res."},{"issue":"9972","key":"10.1016\/j.biopha.2025.118249_bib96","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.biopha.2025.118249_bib97","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jhep.2020.02.033","article-title":"A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis","volume":"73","author":"Kowdley","year":"2020","journal-title":"J. Hepatol."},{"issue":"7","key":"10.1016\/j.biopha.2025.118249_bib98","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.biopha.2025.118249_bib99","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/hep.29569","article-title":"A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis","volume":"67","author":"Kowdley","year":"2018","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.biopha.2025.118249_bib100","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study","volume":"147","author":"Lammers","year":"2014","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.biopha.2025.118249_bib101","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1517\/14656566.2015.998650","article-title":"Advances in pharmacotherapy for primary biliary cirrhosis","volume":"16","author":"Mousa","year":"2015","journal-title":"Expert Opin. Pharmacother."},{"issue":"3","key":"10.1016\/j.biopha.2025.118249_bib102","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1053\/j.gastro.2012.12.005","article-title":"Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid","volume":"144","author":"Carbone","year":"2013","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.biopha.2025.118249_bib103","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","article-title":"Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid","volume":"148","author":"Hirschfield","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.biopha.2025.118249_bib104","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/164_2019_227","article-title":"Obeticholic acid: an update of its pharmacological activities in liver disorders","volume":"256","author":"Fiorucci","year":"2019","journal-title":"Handb. Exp. Pharmacol."},{"issue":"10","key":"10.1016\/j.biopha.2025.118249_bib105","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10102464","article-title":"Obeticholic acid for primary biliary cholangitis","volume":"10","author":"Floreani","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopha.2025.118249_bib106","article-title":"COBALT: a confirmatory trial of obeticholic acid in primary biliary cholangitis with placebo and external controls","author":"Kowdley","year":"2024","journal-title":"Am. J. Gastroenterol."},{"issue":"10","key":"10.1016\/j.biopha.2025.118249_bib107","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/apt.16336","article-title":"Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficult-to-treat primary biliary cholangitis","volume":"53","author":"Soret","year":"2021","journal-title":"Aliment Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2025.118249_bib108","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13098-020-00570-y","article-title":"NAFLD as a continuum: from obesity to metabolic syndrome and diabetes","volume":"12","author":"Godoy-Matos","year":"2020","journal-title":"Diabetol. Metab. Syndr."},{"key":"10.1016\/j.biopha.2025.118249_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.metop.2021.100149","article-title":"Metabolic causes and consequences of nonalcoholic fatty liver disease (NAFLD)","volume":"12","author":"Zarghamravanbakhsh","year":"2021","journal-title":"Metab. Open"},{"issue":"2","key":"10.1016\/j.biopha.2025.118249_bib110","doi-asserted-by":"crossref","first-page":"167","DOI":"10.34172\/mejdd.2022.270","article-title":"Non-alcoholic fatty liver disease and steatohepatitis: risk factors and pathophysiology","volume":"14","author":"Akter","year":"2022","journal-title":"Middle East J. Dig. Dis."},{"issue":"4","key":"10.1016\/j.biopha.2025.118249_bib111","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/hep4.1479","article-title":"Pathogenesis oF Nonalcoholic Steatohepatitis: an overview","volume":"4","author":"Parthasarathy","year":"2020","journal-title":"Hepatol. Commun."},{"issue":"7","key":"10.1016\/j.biopha.2025.118249_bib112","first-page":"371","article-title":"Update on clinical trials for nonalcoholic steatohepatitis","volume":"19","author":"Nathani","year":"2023","journal-title":"Gastroenterol. Hepatol."},{"issue":"10","key":"10.1016\/j.biopha.2025.118249_bib113","first-page":"1169","article-title":"Resmetirom for nonalcoholic steatohepatitis","volume":"29","author":"Fahim","year":"2023","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"10.1016\/j.biopha.2025.118249_bib114","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000001281","article-title":"Assessment of liver injury potential of investigational medicines in drug development","author":"Chalasani","year":"2025","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.biopha.2025.118249_bib115","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jhep.2020.07.028","article-title":"Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis","volume":"74","author":"Kj\u00e6rgaard","year":"2021","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.biopha.2025.118249_bib116","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/liv.15816","article-title":"Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASH","volume":"44","author":"Alkhouri","year":"2024","journal-title":"Liver Int."},{"issue":"6","key":"10.1016\/j.biopha.2025.118249_bib117","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1097\/HEP.0000000000001174","article-title":"Hepatic real-world outcomes with obeticholic acid in primary biliary cholangitis (HEROES): a trial emulation study design","volume":"81","author":"Brookhart","year":"2025","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.biopha.2025.118249_bib118","doi-asserted-by":"crossref","first-page":"263","DOI":"10.14309\/ajg.0000000000003153","article-title":"Correction to COBALT: a confirmatory trial of obeticholic acid in primary biliary cholangitis with placebo and external controls","volume":"120","author":"Kowdley","year":"2025","journal-title":"Am. J. Gastroenterol."},{"issue":"18","key":"10.1016\/j.biopha.2025.118249_bib119","doi-asserted-by":"crossref","DOI":"10.3390\/cells13181580","article-title":"Current landscape and evolving therapies for primary biliary cholangitis","volume":"13","author":"Fiorucci","year":"2024","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.biopha.2025.118249_bib120","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.2353\/ajpath.2009.090114","article-title":"Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts","volume":"175","author":"Fickert","year":"2009","journal-title":"Am. J. Pathol."},{"issue":"4","key":"10.1016\/j.biopha.2025.118249_bib121","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1136\/gut.2010.212159","article-title":"Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease","volume":"60","author":"Gadaleta","year":"2011","journal-title":"Gut"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225004433?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225004433?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T11:48:44Z","timestamp":1754653724000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225004433"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":121,"alternative-id":["S0753332225004433"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118249","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic implications of obeticholic acid, a farnesoid X receptor agonist, in the treatment of liver fibrosis","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118249","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118249"}}